DK0464846T3 - Imidderivater og deres fremstilling og anvendelse - Google Patents
Imidderivater og deres fremstilling og anvendelseInfo
- Publication number
- DK0464846T3 DK0464846T3 DK91111223T DK91111223T DK0464846T3 DK 0464846 T3 DK0464846 T3 DK 0464846T3 DK 91111223 T DK91111223 T DK 91111223T DK 91111223 T DK91111223 T DK 91111223T DK 0464846 T3 DK0464846 T3 DK 0464846T3
- Authority
- DK
- Denmark
- Prior art keywords
- group
- aromatic
- hydrocarbon ring
- aromatic hydrocarbon
- chem
- Prior art date
Links
- 150000003949 imides Chemical class 0.000 title 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- -1 imide compound Chemical class 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18027190 | 1990-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0464846T3 true DK0464846T3 (da) | 1998-11-30 |
Family
ID=16080314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK91111223T DK0464846T3 (da) | 1990-07-06 | 1991-07-05 | Imidderivater og deres fremstilling og anvendelse |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US5532372A (da) |
| EP (1) | EP0464846B1 (da) |
| JP (1) | JP2800953B2 (da) |
| AT (1) | ATE165359T1 (da) |
| CA (1) | CA2046429C (da) |
| DE (2) | DE69129282D1 (da) |
| DK (1) | DK0464846T3 (da) |
| ES (1) | ES2115599T3 (da) |
| GR (1) | GR3026697T3 (da) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5561128A (en) * | 1989-05-19 | 1996-10-01 | Hoechst-Roussel Pharmaceuticals, Inc. | N-[(4-(heteroaryl)-1-piperidinyl)alkyl]-10,11-dihydro-5H-dibenz[B,F]azepines and related compounds and their therapeutic utility |
| US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| GB9202915D0 (en) * | 1992-02-12 | 1992-03-25 | Wellcome Found | Chemical compounds |
| TW421649B (en) * | 1995-01-31 | 2001-02-11 | Janssen Pharmaceutica Nv | 4-(1H-indol-1yl)-1-piperidinyl derivatives |
| US6576636B2 (en) * | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| JPH10204012A (ja) * | 1997-01-24 | 1998-08-04 | Daicel Chem Ind Ltd | ３−ヒドロキシメチルシクロアルカノール類およびその製造方法 |
| GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
| US6225444B1 (en) | 1998-02-10 | 2001-05-01 | Protarga, Inc. | Neuroprotective peptides and uses thereof |
| GB9810876D0 (en) | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
| US7235583B1 (en) * | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
| US7001911B2 (en) | 2000-06-28 | 2006-02-21 | Bristol-Myers Squibb Company | Fused cyclic modulators of nuclear hormone receptor function |
| US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| HUP0303172A3 (en) * | 2000-06-28 | 2006-05-29 | Bristol Myers Squibb Co | Selective androgen receptor modulators and methods for their identification, desing and use |
| EP1854798A3 (en) * | 2000-09-19 | 2007-11-28 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| AU2001286237A1 (en) * | 2000-09-22 | 2002-04-02 | Sumitomo Pharmaceuticals Company, Limited | Oral preparations with favorable disintegration characteristics |
| US20040087548A1 (en) | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| AU2002303164A1 (en) | 2001-03-23 | 2002-10-08 | Protarga, Inc. | Fatty amine drug conjugates |
| AU2002305099A1 (en) * | 2001-03-23 | 2002-10-08 | Protarga, Inc. | Fatty alcohol drug conjugates |
| US7087636B2 (en) * | 2001-12-19 | 2006-08-08 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function |
| JP3977162B2 (ja) * | 2002-06-21 | 2007-09-19 | 株式会社バンダイナムコゲームス | キャラクタ情報管理装置、プログラム及び情報記憶媒体 |
| ES2685780T3 (es) | 2002-08-22 | 2018-10-11 | Sumitomo Dainippon Pharma Co., Ltd. | Agente para el tratamiento de esquizofrenia |
| KR101113630B1 (ko) * | 2003-06-23 | 2012-02-13 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 노인성 치매 치료제 |
| BRPI0413081B8 (pt) * | 2003-07-29 | 2021-05-25 | Dainippon Sumitomo Pharma Co | processo para produzir o cloridrato do composto imida |
| KR100578104B1 (ko) * | 2003-12-16 | 2006-05-10 | 한국과학기술원 | 코발트-질소 박막을 이용한 코발트 다이실리사이드에피층의 형성방법 |
| EP1726952A4 (en) * | 2004-02-20 | 2008-06-18 | Dainippon Sumitomo Pharma Co | METHOD FOR IN VIVO SCREENING OF A THERAPEUTIC FOR A MEMORY / LEARNING FUNCTION THROUGH SCHIZOPHRENIA |
| JP2006169154A (ja) * | 2004-12-15 | 2006-06-29 | Sumitomo Chemical Co Ltd | 第四級アンモニウム塩の製造方法 |
| JP4708012B2 (ja) * | 2004-12-15 | 2011-06-22 | 大日本住友製薬株式会社 | 第四級アンモニウム塩の製造法 |
| JP4799892B2 (ja) * | 2005-03-31 | 2011-10-26 | 住友化学株式会社 | シクロヘキサン誘導体およびその製造方法 |
| SI1884242T1 (sl) * | 2005-05-26 | 2013-07-31 | Dainippon Sumitomo Pharma Co., Ltd. | Farmacevtski sestavek, ki vsebuje lurazidon |
| EP1891956B1 (en) * | 2005-06-13 | 2012-08-29 | Dainippon Sumitomo Pharma Co., Ltd. | Solubilization preparation |
| HRP20130041T8 (en) * | 2007-04-04 | 2013-03-31 | Merck Sharp & Dohme Corp. | Therapeutic agents |
| US20090076027A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched lurasidone |
| WO2009101940A1 (ja) | 2008-02-11 | 2009-08-20 | Dainippon Sumitomo Pharma Co., Ltd. | 溶出性の改善された錠剤 |
| US20110003994A1 (en) | 2009-07-02 | 2011-01-06 | Dainippon Sumitomo Pharma Co., Ltd. | Cycloalkane derivative |
| US20110124659A1 (en) * | 2009-11-17 | 2011-05-26 | Dainippon Sumitomo Pharma Co., Ltd. | Cycloalkane derivative |
| JP5317939B2 (ja) * | 2009-12-02 | 2013-10-16 | 住友化学株式会社 | アルコール化合物の製造方法 |
| WO2011093522A1 (en) * | 2010-01-28 | 2011-08-04 | Dainippon Sumitomo Pharma Co., Ltd. | A cycloalkane derivative |
| US8735397B2 (en) * | 2010-03-29 | 2014-05-27 | Vanderbilt University | Method for treating schizophrenia and related diseases |
| JP5820822B2 (ja) * | 2010-04-26 | 2015-11-24 | 大日本住友製薬株式会社 | リン酸塩を用いる第四級アンモニウム塩の製造法 |
| WO2011136383A1 (en) * | 2010-04-26 | 2011-11-03 | Dainippon Sumitomo Pharma Co., Ltd. | A process of a quaternary ammonium salt |
| US9469630B2 (en) * | 2010-10-18 | 2016-10-18 | Sumitomo Dainippon Pharma Co., Ltd. | Sustained-release formulation for injection |
| US8258139B2 (en) | 2010-11-08 | 2012-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
| AU2011328993B2 (en) | 2010-11-15 | 2017-03-02 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| WO2012107890A2 (en) * | 2011-02-10 | 2012-08-16 | Ranbaxy Laboratories Limited | Crystalline forms of lurasidone hydrochloride |
| WO2012123858A1 (en) | 2011-03-14 | 2012-09-20 | Ranbaxy Laboratories Limited | Amorphous lurasidone hydrochloride |
| ES2972387T3 (es) | 2011-03-18 | 2024-06-12 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden ésteres de sorbitán |
| WO2012131606A1 (en) | 2011-04-01 | 2012-10-04 | Ranbaxy Laboratories Limited | Process for the preparation of an antipsychotic agent |
| CN102731512B (zh) * | 2011-04-12 | 2015-04-22 | 天津药物研究院 | 一种鲁拉西酮中间体及鲁拉西酮的制备方法 |
| US9433620B2 (en) | 2011-05-13 | 2016-09-06 | Cadila Healthcare Limited | Pharmaceutical compositions of lurasidone |
| EP2736905A4 (en) * | 2011-07-28 | 2015-07-29 | Mapi Pharma Ltd | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF |
| CN102911169B (zh) * | 2011-08-02 | 2015-05-06 | 上海医药工业研究院 | 一种卢拉西酮的制备方法 |
| WO2013030722A1 (en) | 2011-08-26 | 2013-03-07 | Ranbaxy Laboratories Limited | Crystalline lurasidone hydrochloride |
| CN103130794B (zh) * | 2011-12-02 | 2016-06-22 | 苏州二叶制药有限公司 | 卢拉西酮盐酸盐的晶体a的制备方法 |
| CN103130795A (zh) * | 2011-12-02 | 2013-06-05 | 苏州二叶制药有限公司 | 卢拉西酮盐酸盐的晶体a及其用途 |
| US9409899B2 (en) | 2012-02-13 | 2016-08-09 | Cadila Healthcare Limited | Process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclo hexylmethanisoindol-1,3-dione and its intermediates |
| US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
| CA2867121C (en) * | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| WO2013142202A1 (en) * | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising glycerol esters |
| CN103360383B (zh) * | 2012-04-11 | 2016-07-06 | 上海医药工业研究院 | 鲁拉西酮盐酸盐的晶型b及其制备方法 |
| US10052319B2 (en) | 2012-04-26 | 2018-08-21 | Sumitomo Dainippon Pharma Co., Ltd. | Medicament for treating mental and behavioural disorders |
| CN102746289B (zh) * | 2012-04-28 | 2016-06-08 | 上海医药工业研究院 | 一种盐酸卢拉西酮的制备方法 |
| CN103450172A (zh) * | 2012-05-30 | 2013-12-18 | 广州药源生物医药科技有限公司 | 一种抗精神病药物鲁拉西酮的制备方法 |
| WO2013190455A2 (en) * | 2012-06-18 | 2013-12-27 | Shasun Pharmaceuticals Limited | Process for the preparation of lurasidone hydrochloride |
| EP2874628B1 (en) * | 2012-07-18 | 2017-12-13 | Shasun Pharmaceuticals Limited | Salts and hydrates of antipsychotics |
| WO2014037886A1 (en) | 2012-09-04 | 2014-03-13 | Ranbaxy Laboratories Limited | Process for the preparation of lurasidone hydrochloride |
| JP6654042B2 (ja) | 2012-09-19 | 2020-02-26 | アルカームス ファーマ アイルランド リミテッド | 貯蔵安定性が改善された医薬組成物 |
| CN102827157A (zh) * | 2012-09-20 | 2012-12-19 | 北京哈三联科技股份有限公司 | 一种制备鲁拉西酮的方法 |
| WO2014064714A2 (en) * | 2012-10-22 | 2014-05-01 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for preparation of lurasidone hydrochloride |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| CN103864774B (zh) * | 2012-12-14 | 2016-09-28 | 成都弘达药业有限公司 | 一种鲁拉西酮的制备方法 |
| WO2014102808A1 (en) | 2012-12-25 | 2014-07-03 | Lee Pharma Limited | A process for preparation of trans (lr,2r)-cyclo hexane 1, 2-dicarboxylic acid |
| WO2014102834A2 (en) * | 2012-12-31 | 2014-07-03 | Hetero Research Foundation | Process for lurasidone |
| ITMI20130262A1 (it) * | 2013-02-22 | 2014-08-23 | Edmond Pharma Srl | Procedimento per la preparazione di lurasidone cloridrato |
| CN104031041A (zh) * | 2013-03-06 | 2014-09-10 | 江苏恩华药业股份有限公司 | 盐酸鲁拉西酮的新晶型及其制备方法 |
| CN104513182A (zh) * | 2013-10-08 | 2015-04-15 | 无锡万全医药技术有限公司 | 一种(1r,2r)-1,2-环己烷二甲醇二磺酸酯的制备方法 |
| ITMI20131737A1 (it) | 2013-10-17 | 2015-04-18 | Procos Spa | Processo per la sintesi industriale di lurasidone |
| CZ306203B6 (cs) | 2013-12-06 | 2016-09-29 | Zentiva, K. S | Způsob syntézy lurasidonu |
| EP4032889B1 (en) | 2013-12-20 | 2026-05-06 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| AU2015231278B2 (en) | 2014-03-20 | 2020-01-23 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
| JP6594351B2 (ja) | 2014-06-16 | 2019-10-23 | ジョンソン、マッセイ、パブリック、リミテッド、カンパニー | 新規中間体を含むアルキル化アリールピペラジン及びアルキル化アリールピペリジン化合物の製造方法 |
| WO2016012898A1 (en) | 2014-07-25 | 2016-01-28 | Lupin Limited | Oral pharmaceutical composition of lurasidone |
| WO2016059649A1 (en) * | 2014-10-14 | 2016-04-21 | Jubilant Generics Limited (Formerly Jubilant Life Sciences Division) | An improved process for the preparation of lurasidone hydrochloride |
| CN106146486A (zh) * | 2015-04-21 | 2016-11-23 | 上海医药集团股份有限公司 | 一种制备高纯度高收率鲁拉西酮的方法 |
| EP3310785B1 (en) | 2015-06-19 | 2024-11-20 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2018015915A1 (en) | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN110114063B (zh) | 2017-01-06 | 2022-01-11 | 广东东阳光药业有限公司 | 鲁拉西酮固体分散体及其制备方法 |
| JPWO2019167978A1 (ja) | 2018-02-28 | 2021-02-04 | 大日本住友製薬株式会社 | 溶出が制御された水性懸濁型医薬製剤 |
| CN111989102A (zh) | 2018-02-28 | 2020-11-24 | 大日本住友制药株式会社 | 水性混悬液型药物制剂 |
| AU2019230014B2 (en) | 2018-03-05 | 2024-11-28 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| AU2019288382B2 (en) | 2018-06-19 | 2024-07-25 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN113024535B (zh) | 2019-12-24 | 2024-08-02 | 上海科胜药物研发有限公司 | 一种鲁拉西酮盐酸盐的制备方法 |
| JP7828459B2 (ja) * | 2022-01-11 | 2026-03-11 | スヴェン・ライフ・サイエンシーズ・リミテッド | ヘテロ脂環式誘導体及びｃｎｓ障害の治療におけるそれらの使用 |
| EP4572852A1 (en) | 2022-08-19 | 2025-06-25 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN117285530B (zh) * | 2023-08-03 | 2026-01-16 | 迪嘉药业集团股份有限公司 | 一种盐酸鲁拉西酮新制备方法 |
| WO2026089567A1 (ko) * | 2024-10-25 | 2026-04-30 | 주식회사 비보존 | 헤테로사이클 화합물 및 이의 용도 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2421900A1 (fr) * | 1977-03-17 | 1979-11-02 | Sauba Lab | Piperazino-3-indoles, leur procede de preparation et leurs applications therapeutiques |
| EP0009465A1 (de) * | 1978-09-20 | 1980-04-02 | Ciba-Geigy Ag | N-(1-(4-Amino-2-chinazolinyl)-3- oder -4-piperidyl-lactame, Verfahren zu ihrer Herstellung, sowie pharmazeutische Präparate enthaltend diese Verbindungen |
| US4355037A (en) * | 1981-11-12 | 1982-10-19 | Hoechst-Roussel Pharmaceuticals | 3-(4-Piperidyl)-1,2-benzisoxales |
| US4411901A (en) * | 1981-12-23 | 1983-10-25 | Mead Johnson & Company | Benzisothiazole and benzisoxazole piperazine derivatives |
| US4507303A (en) * | 1981-12-22 | 1985-03-26 | Sumitomo Chemical Company, Limited | Succinimide derivatives, compositions and method of use |
| JPS5976059A (ja) * | 1982-10-21 | 1984-04-28 | Sumitomo Chem Co Ltd | 環状イミド誘導体及びその酸付加塩 |
| NL8401907A (nl) * | 1983-06-27 | 1985-01-16 | Sandoz Ag | Spirosuccinimiden en werkwijzen voor het bereiden en toepassen van deze spirosuccinimiden. |
| US4590196A (en) * | 1984-08-23 | 1986-05-20 | Bristol-Myers Company | Analgesic 1,2-benzisothiazol-3-ylpiperazine derivatives |
| JPH0625181B2 (ja) * | 1985-03-27 | 1994-04-06 | 住友製薬株式会社 | 新規なイミド誘導体 |
| JPS61238784A (ja) * | 1985-04-17 | 1986-10-24 | Sumitomo Seiyaku Kk | コハク酸イミド誘導体及びその酸付加塩 |
| US4656173A (en) * | 1985-04-24 | 1987-04-07 | Bristol-Myers Company | Antipsychotic benzisothiazole S-oxide compound |
| AU593194B2 (en) * | 1986-09-26 | 1990-02-01 | Sumitomo Pharmaceuticals Company, Limited | Imide derivatives ,and their production and use |
| CA1335289C (en) * | 1987-10-26 | 1995-04-18 | Fujio Antoku | Piperidinyl benzisoxazole derivatives, their production and pharmaceutical use |
-
1991
- 1991-06-27 JP JP3183640A patent/JP2800953B2/ja not_active Expired - Lifetime
- 1991-07-05 CA CA002046429A patent/CA2046429C/en not_active Expired - Lifetime
- 1991-07-05 DE DE69129282A patent/DE69129282D1/de not_active Expired - Lifetime
- 1991-07-05 EP EP91111223A patent/EP0464846B1/en not_active Expired - Lifetime
- 1991-07-05 DK DK91111223T patent/DK0464846T3/da active
- 1991-07-05 DE DE69129282T patent/DE69129282T4/de not_active Expired - Lifetime
- 1991-07-05 AT AT91111223T patent/ATE165359T1/de not_active IP Right Cessation
- 1991-07-05 ES ES91111223T patent/ES2115599T3/es not_active Expired - Lifetime
-
1993
- 1993-08-30 US US08/113,320 patent/US5532372A/en not_active Expired - Lifetime
-
1996
- 1996-04-18 US US08/634,738 patent/US5780632A/en not_active Expired - Lifetime
-
1998
- 1998-04-23 GR GR980400561T patent/GR3026697T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0464846A1 (en) | 1992-01-08 |
| JP2800953B2 (ja) | 1998-09-21 |
| CA2046429C (en) | 2003-09-16 |
| CA2046429A1 (en) | 1992-01-07 |
| DE69129282D1 (de) | 1998-05-28 |
| GR3026697T3 (en) | 1998-07-31 |
| US5780632A (en) | 1998-07-14 |
| EP0464846B1 (en) | 1998-04-22 |
| ATE165359T1 (de) | 1998-05-15 |
| DE69129282T4 (de) | 2011-01-13 |
| US5532372A (en) | 1996-07-02 |
| JPH0517440A (ja) | 1993-01-26 |
| DE69129282T2 (de) | 1998-08-20 |
| ES2115599T3 (es) | 1998-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2115599T3 (es) | Derivados de imidas su preparacion y utilizacion. | |
| ATE117295T1 (de) | 4-oxochinolin-3-carbonsäure-derivate, ihre herstellung und ihre verwendung. | |
| DE3781716D1 (de) | Mittel zur ortsspezifischen alkylierung. | |
| DE3061883D1 (en) | Imidazole guanidines, their preparation and compositions containing them | |
| PT99919A (pt) | Processo para a preparacao de derivados de xantina | |
| FI953710A0 (fi) | Uusia pyrrolokarbatsoleja | |
| ATE45354T1 (de) | Chinoloncarbonsaeurederivate. | |
| DK0518558T3 (da) | 1-methylcarbapenemderivater, deres fremstilling og deres anvendelse som antibiotika | |
| DE68905407D1 (de) | Analgetische carbonsaeureamid-derivate. | |
| PT88003A (pt) | Processo para a preparacao de di-hidropiridinas condensadas com um anel carbociclico ou heterociclico | |
| KR920016448A (ko) | 피페리딘 유도체 | |
| DE68927311D1 (de) | Buten- oder Propensäure-Derivate | |
| ATE207058T1 (de) | Amine derivate, ihre herstellung und anwendung | |
| DE68926810D1 (de) | Benzoxazepinon-Verfahren | |
| EP0485219A3 (en) | Medicaments for preventing and treating circulatory organ diseases containing spiro-3-heteroazolidine compounds | |
| ATE73759T1 (de) | Fungizide. | |
| ATE71370T1 (de) | 2-amino-5-hydroxy-4-pyrimidone. | |
| NO179835C (no) | Aminderivater med fungicid aktivitet og anvendelse som fungicider | |
| IT1217900B (it) | Composti eterociclici azotati ad azione antifungina |